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Abstract
Background: Neuropathy is a rare adverse side effect of disulfiram therapy and is under-recognized. There have
been few case reports documenting this side effect.
Case presentation: Two cases of disulfiram peripheral neuropathy are discussed. The first case is that of a
25-year-old Caucasian woman who was exposed to disulfiram therapy for a total of 8 months and developed
pain and stiffness that prevented her from walking. The second case is that of a 46-year-old Caucasian woman who
developed sudden-onset numbness in her lower extremities with progression to pain. Her symptoms improved over
the course of 2 months after cessation of disulfiram therapy. In both cases, symptoms improved after cessation of
disulfiram therapy.
Conclusions: Disulfiram neuropathy occurs in persons with a history of chronic alcohol use. It is under-recognized and
often attributed to alcoholic neuropathy given its comorbidity with alcoholic neuropathy. A greater understanding of
this side effect may reduce neurologic complications related to disulfiram neuropathy and aid in early withdrawal of
this offending agent.
Background
Disulfiram is typically used as a second-line agent for
treating chronic alcoholism. Alcohol is metabolized by
alcohol dehydrogenase to acetaldehyde, which is then
broken down by aldehyde dehydrogenase to acetic acid
and excreted. Disulfiram’s main mechanism of action is
to inhibit aldehyde dehydrogenase, thereby increasing
serum acetaldehyde levels. When alcohol is taken in
conjunction with disulfiram, the drug interaction results
in high levels of acetaldehyde. This produces an unpleas-
ant physiologic reaction, causing patients to have “hang-
over” symptoms such as nausea, palpitations, flushing,
vertigo, and chest pain. Adverse reactions have been
documented in both the central and peripheral nervous
systems. In the central nervous system, adverse reactions
include drowsiness, headache, fatigue, polyneuritis, and
psychosis. Adverse reactions in the peripheral nervous
system include peripheral neuritis and peripheral neur-
opathy. Several authors have suggested that this physio-
logic reaction is dose-dependent and related to an
accumulation of carbon disulfide, which is a by-product
of the metabolism of disulfiram in the liver [1].
Disulfiram neuropathy has been described as a distal
axonopathy related to the “dying-back” effect of axonal
degeneration [2–4]. The frequency of these adverse reac-
tions has not been defined. A brief literature review




Our first patient was a 25-year-old Caucasian woman
who was referred to our tertiary neuromuscular clinic
for a second opinion regarding her neuropathy. She had
a history of heavy alcohol use from ages 18 to 23, during
which she consumed as many as eight to ten drinks per
day. She first had sensory symptoms at age 22, described
as numbness of her feet as if they were “falling asleep.”
She initially did not pay attention to the symptoms.
Gradually, her symptoms progressed and included burn-
ing, electric shock sensation, and allodynia to objects
including bed sheets, socks, and the floor when walking
barefoot. She was placed on disulfiram therapy (500 mg
orally every morning) for 6 months, then discontinued
for several months before it was reinstituted for an
additional 2 months at the same dose. By the eighth
month of therapy, she was unable to walk owing to
severe symptoms of pain and stiffness in her legs. She
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also noted symptoms in her hands. She stopped taking
the disulfiram and was able to walk within a few weeks,
but she continued to have pain and numbness.
She had seen a community neurologist prior to seek-
ing a second opinion in our clinic. Laboratory studies
completed previously showed normal levels of HbA1c,
vitamins B1 and B12, folate, Sjögren syndrome antigen
A and B antibodies, antinuclear antibody, antineutrophil
cytoplasmic antibodies, and antigliadin antibodies. She
had monoclonal gammopathy, and results of a sensori-
motor neuropathy antibody panel were within normal
limits. Pertinent examination findings showed that she
had normal motor function except for decreased bulk in
her extensor digitorum brevis. A sensory examination
showed a gradient distribution decrease in light touch,
temperature, and pinprick distally, along with decreased
vibration and position sense at her toes. Her gait and
reflexes were normal. Electrodiagnostic studies showed a
severe length-dependent motor neuropathy, as evidenced
by a significantly decreased amplitude in the compound
motor action potential (CMAP) in her lower extremities
with a preserved CMAP in her upper extremities. There
was sparing of her large fiber sensory nerves, as evidenced
by normal sensory nerve action potentials (SNAPs). Both
right and left posterior tibial CMAP waveforms showed
temporal dispersion as well as prolonged duration. Elec-
tromyography (EMG) was performed on selected muscles
in her bilateral lower extremities and revealed 2+ fibrilla-
tion potentials and positive sharp waves in her abductor
hallucis muscles. Also seen were polyphasia, increased
amplitude and increased duration with decreased recruit-
ment, and increased firing rate to most muscles sampled.
Case 2
Our second patient was a 46-year-old Caucasian woman
who was being followed by a community neurologist, to
whom she reported sudden onset bilateral numbness of
her feet when walking. She had progressively worsening
symptoms, including freezing/burning pain, and allody-
nia to bed sheets and when walking barefoot. She was
initially referred to our tertiary neuromuscular clinic;
however, she was admitted to the Keck Medical Hospital
owing to the acutely progressive nature of her symp-
toms. During her hospital stay she had an unremarkable
workup, including lumbar puncture, cervical and thor-
acic MRI, as well as chest, abdominal, and pelvic CT.
Results from an additional laboratory workup, including
testing for vitamin B12, folate, TSH, rapid plasma reagin,
heavy metals, HbA1c, and homocysteine, and a serum
electrophoresis were normal.
She presented to our clinic a month after being dis-
charged from the hospital. She reported a 3-month
history of sudden-onset numbness in both feet that had
worsened and which she described as a frostbite
sensation of freezing and burning. She had allodynia to
bed sheets and walking barefoot that she described as a
sensation of “walking on pegs.” Her social history
showed heavy alcohol use of one bottle of wine daily.
She had taken disulfiram at a dose of 500 mg daily but
had stopped the medication a couple of weeks prior to
her hospital admission when she developed symptoms of
neuropathy. Since her discharge from hospital, she
reported that she was no longer feeling pain and that
the frostbite sensation had improved. Pertinent findings
included normal results from a motor examination
except for weaker bilateral ankle dorsiflexion. A sensory
examination showed distal changes including absent
position sense at the toes, significantly decreased vibra-
tion at the toes, and absent light touch and pinprick to
the distal 5 cm of her feet. Electrodiagnostic testing was
performed several weeks after her initial clinic visit and
a nerve conduction study revealed severe motor axonal
neuropathy in her lower extremity nerves with length-
dependent characteristics. Her bilateral peroneal CMAPs
were significantly decreased. By contrast, her upper
extremity CMAP parameters were normal. There was
sparing of her large fiber sensory nerves as evidenced by
normal SNAPs. EMG showed 1+ positive sharp waves and
fibrillation potentials in most of the sampled muscles of
her lower extremities. There were slight to moderate
increases in the amplitudes of the motor unit potentials as
well as increased polyphasia.
Please see Tables 1 and 2 for electrodiagnostic data for
both patients.
Discussion
Distal axonopathy is considered the hallmark of disulfiram
toxicity and was evident in these two cases. Axonopathy is
demonstrated by the low CMAPs with relatively normal
motor conduction velocities. The length-dependent nature
of the disulfiram neuropathy was demonstrated by the
severely decreased CMAP in the lower extremities while
the upper extremities were spared. Demyelination was not
supported by the results of either laboratory studies or
electrodiagnostic testing. Studies suggest the causal agent
of disulfiram neuropathy is carbon disulfide, which is a
by-product of disulfiram metabolization [1]. Ansbacher
et al. reported a case in which a sural nerve biopsy dem-
onstrated neurofilamentous distal axonopathy and cited
carbon disulfide as the responsible agent. Clinically,
disulfiram neuropathy and alcoholic neuropathy can be
difficult to distinguish. Some observations that can help
distinguish the two include a history of onset that occurs
in a matter of weeks in disulfiram neuropathy as opposed
to an insidious course over months in alcoholic neur-
opathy. Additionally, the progression is faster in disulfiram
neuropathy [5]. Symptoms of both types of neuropathy
can be similar, such as symmetrical distribution, worse
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severity distally, and depression of ankle jerk reflexes. In
contrast to alcohol neuropathy, disulfiram neuropathy
results in muscle tenderness as well as disturbances in
sweating of distal limbs [6]. In our two cases, our patients
presented with distal lower extremity symptoms of pre-
dominantly painful sensory complaints. Our patient in
case 1 had pre-existing symptoms prior to disulfiram ther-
apy, but experienced an acute worsening of symptoms
following disulfiram therapy. Our patient in case 2 had
lower extremity symptoms of sudden onset and a tem-
poral relationship with disulfiram therapy. Symptoms in
both patients progressed at a faster rate than typically
observed with alcoholic neuropathy at a time when both
were abstaining from alcohol. Clinically, symptoms im-
proved in both patients after cessation of disulfiram; most
notably, our patient in case 2 was free of pain 2 months
after stopping disulfiram. Electrodiagnostic tests in both
patients demonstrated severe length-dependent axonopa-
thy with low distal CMAPs in their lower extremities but
normal CMAPs in their upper extremities. EMG studies
showed both active denervation, as evidenced by fibrilla-
tion and positive sharp waves, as well as chronic
denervation, demonstrated by increased amplitude and
polyphasia. Additionally, although the primary complaint
was sensory in both patients, their SNAPs were spared.
This suggests the involvement of small fiber sensory
nerves but the sparing of large fiber sensory nerves. This
is in contrast to prior literature that report large fiber
involvement in disulfiram neuropathy [5, 6]. Unfortu-
nately, both of our patients declined repeat electrodiag-
nostic testing and hence it was not possible to document a
correlation between clinical and electrophysiological find-
ings. Although not routinely performed in the evaluation
of disulfiram neuropathy, perhaps sensory nerve biopsies
would help elucidate any such correlation.
Conclusions
Disulfiram neuropathy occurs in patients who have a
history of chronic alcohol use. The frequency with which
it occurs is difficult to assess, though one quoted figure
is 1:15,000 [5, 7]. The challenge in determining
disulfiram as the causative agent is that concomitant
alcohol-related neuropathy is often a confounding factor;
thus, disulfiram neuropathy is likely under-diagnosed
and attributed to alcohol neuropathy. Often, clinicians
must rely on the timing of neuropathic complaints with
respect to disulfiram administration. As with case 1, our
patient had sensory complaints prior to starting
disulfiram therapy; however, she experienced acute wors-
ening of her symptoms after initiating therapy at a time
when she was abstaining from alcohol. Additionally, her
symptoms improved with cessation of disulfiram. In
case 2, our patient’s neuropathic symptoms clearly devel-
oped after she started disulfiram therapy. Her symptoms
improved over the course of 2 months after the cessation
of therapy. Because the underlying neuropathy due to
alcohol is a confounder, we propose further study of the
potential effects of disulfiram on peripheral nerves. One
method to study this would be to perform electrodiagnos-
tic studies prior to initiating disulfiram therapy to obtain a
baseline. Neuropathy and electrodiagnostic findings of de-
creased CMAP to indicate axonopathy after disulfiram
Table 2 Summary of electrodiagnostic data – sensory studies
Nerve (normal values) Case 1 Case 2
Right Left Right Left
Sural
Lat (m/s) (<4.4) 3.2 3.8 3.6 3.4
Amp (mV) (>5.9) 10.24 11.33 4.25 8.35
CV (m/s) (>39) 43.7 45.4 48.2 48.2
Median
Lat (m/s) (<3.8) N/A 3.0 N/A 3.6
Amp (mV) (>19) N/A 44.64 N/A 57.09
CV (m/s) (>49) N/A 59.8 N/A 47.2
Ulnar
Lat (m/s) (<3.7) N/A 3.0 N/A 3.2
Amp (mV) (>16) N/A 25.92 N/A 28.38
CV (m/s) (>49) N/A 58.3 N/A 51.8
CV conduction velocity, Lat latency, Amp amplitude, m meter, s second,
mV millivolt
Table 1 Summary of electrodiagnostic data – motor studies
Nerve (normal values) Case 1 Case 2
Right Left Right Left
Tibial
Lat (m/s) (<5.9) 5.3 3.6 6.6 4.6
Amp (mV) (>3) 0.8 0.9 0.3 0.0
CV (m/s) (>39) 34.3 39 52.5 N/A
Peroneal
Lat (m/s) (<6.5) 4.7 5.0 3.7 8.5
Amp (mV) (>2.1) 1.8 0.9 0.1 0.1
CV (m/s) (>39) 45.1 46.8 34.9 38.7
Median
Lat (m/s) (<4.5) N/A 2.3 N/A 4.0
Amp (mV) (>4.9) N/A 12.1 N/A 7.2
CV (m/s) (>48) N/A 54.2 N/A 54.3
Ulnar
Lat (m/s) (<4.5) N/A 2.3 N/A 2.7
Amp (mV) (>4.9) N/A 11.3 N/A 7.6
CV (m/s) (>48) N/A 55.1 N/A 58.3
CV conduction velocity, Lat latency, Amp amplitude, m meter, s second,
mV millivolt
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therapy can then be attributed to disulfiram with greater
confidence, given that patients will have abstained from al-
cohol during disulfiram therapy. Another useful study
may be to perform a sensory nerve biopsy to determine if
small fiber sensory nerves are involved.
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